Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vella

Showing results (161-170 of 171) with videos related to

Pageof 18
Sort By:
Psychiatry and Clinical Neurosciences|March 17, 2026
Disturbing dreams and dementia incidence across diverse cohort studies: A COSMIC collaboration studyDarren M Lipnicki, Ashleigh S Vella, Erico Castro-Costa, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|February 3, 1999
A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced diseaseM Floridia, R Bucciardini, D Ricciardulli, et al.
American Journal of Epidemiology|June 2, 2026
Development and validation of a dementia risk prediction model for low- and middle-income countries: the 10/66 studyEduwin Pakpahan, Zhongyang Guan, Mario Siervo, et al.
JAMA|January 27, 2000
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA PanelC C Carpenter, D A Cooper, M A Fischl, et al.
The Journal of Infectious Diseases|April 1, 1997
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replicationM D de Jong, S Vella, A Carr, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthAshleigh S Vella, Keshuo Lin, Darren M Lipnicki, et al.
AIDS Research and Human Retroviruses|December 16, 2000
A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infectionM Floridia, C Tomino, R Bucciardini, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2000
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesK Van Vaerenbergh, K Van Laethem, J Albert, et al.
JACC. Cardiovascular Interventions|June 25, 2025
15-Year Outcomes of PFO Closure in Patients With Cryptogenic Embolism: Insights From the PROLONG RegistryCarlo Gaspardone, Daniela Trabattoni, Daniele O d'Atri, et al.
JACC. Advances|June 30, 2026
Tailoring Antiplatelet Therapy Duration After PFO Closure: Insights From the PROLONG RegistryCarlo Gaspardone, Daniela Trabattoni, Daniele O d'Atri, et al.
Pageof 18

Showing results (161-170 of 171) with videos related to

Sort By:
Pageof 18
Psychiatry and Clinical Neurosciences|March 17, 2026
Disturbing dreams and dementia incidence across diverse cohort studies: A COSMIC collaboration studyDarren M Lipnicki, Ashleigh S Vella, Erico Castro-Costa, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|February 3, 1999
A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced diseaseM Floridia, R Bucciardini, D Ricciardulli, et al.
American Journal of Epidemiology|June 2, 2026
Development and validation of a dementia risk prediction model for low- and middle-income countries: the 10/66 studyEduwin Pakpahan, Zhongyang Guan, Mario Siervo, et al.
JAMA|January 27, 2000
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA PanelC C Carpenter, D A Cooper, M A Fischl, et al.
The Journal of Infectious Diseases|April 1, 1997
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replicationM D de Jong, S Vella, A Carr, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthAshleigh S Vella, Keshuo Lin, Darren M Lipnicki, et al.
AIDS Research and Human Retroviruses|December 16, 2000
A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infectionM Floridia, C Tomino, R Bucciardini, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2000
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analoguesK Van Vaerenbergh, K Van Laethem, J Albert, et al.
JACC. Cardiovascular Interventions|June 25, 2025
15-Year Outcomes of PFO Closure in Patients With Cryptogenic Embolism: Insights From the PROLONG RegistryCarlo Gaspardone, Daniela Trabattoni, Daniele O d'Atri, et al.
JACC. Advances|June 30, 2026
Tailoring Antiplatelet Therapy Duration After PFO Closure: Insights From the PROLONG RegistryCarlo Gaspardone, Daniela Trabattoni, Daniele O d'Atri, et al.
Pageof 18